Nature in Capsule Albumin Classic S
Natural health product licensed in Canada
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 10 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Dose déclarée au-delà d'une limite
Fer: up to 45 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 14 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Fer: up to 45 mg a day according to the dosing instructions published by Health Canada, above the safe level from EFSAEuropean Food Safety Authority. for adults (40 mg a day). Exceeding it does not, on its own, characterise a risk: EFSA could not set an upper limit for this nutrient. The EFSA reference covers total daily intake, from food and supplements.
niveau de sécurité. EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitamine E Source : Succinate d'acide de d-alpha tocophéryle | 30.15 mg AT | Not calculated |
| Riboflavine Source : Riboflavine | 2 mg | 4,000 µg |
| L-Glutamine Source : L-Glutamine | 50 mg | Not calculated |
| Niacinamide Source : Niacinamide | 40 mg | Not calculated |
| Gelée Royale Source : Apis mellifera - sécrétion | 50 mg | Not calculated |
| Panax ginseng Source : Panax ginseng - racine | 45 mg | Not calculated |
| Irvingia gabonensis Source : Irvingia gabonensis - Graine Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 1,500 mg Potency : 7 % Albumin | 150 mg | Not calculated |
| L-Leucine Source : L-Leucine | 50 mg | Not calculated |
| Silybum marianum Source : Silybum marianum - Graine Extract : Matériel brut sec Extraction ratio : 25:1 Dry plant equivalent : 2,500 mg Potency : 80 % Silymarin | 100 mg | Not calculated |
| Vitamine C Source : Acide ascorbique | 20 mg | 40,000 µg |
| Thiamine Source : Chlorhydrate de thiamine | 5 mg | 10,000 µg |
| Vitamine B6 Source : Chlorhydrate de pyridoxine | 5 mg | 10,000 µg |
| Vitamine B12 Source : Cyanocobalamine | 30 microgram | 60 µg |
| Fer Source : Fumarate de fer (II) | 22.5 mg | 45,000 µg |
Non-medicinal ingredients
Gélatine, Cellulose microcristalline, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Could be a complement to a healthy lifestyle that incorporates a calorie-reduced diet and regular physical activity for individuals involved in a weight management program. Helps support healthy cholesterol levels/Helps support cardiovascular health by reducing total and LDL cholesterol. Helps support healthy glucose levels. Helps to maintain/support the body's ability to metabolize nutrients. Helps to prevent iron deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Product record
- Licence holder
- Infinitree Corp.
- NPN or DIN-HM
- 80123067
- Status
- Active licence
- Licence date
- 7 February 2023
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
Source
Official Health Canada record, licence 80123067
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- L-Glutamine
Read the warning, when it applies and the studies cited
L-Glutamine
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
- Gelée Royale
Read the warning, when it applies and the studies cited
ROYAL JELLY
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Contraindications
Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).
Sources cited by Health Canada (8)
- Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Case report
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).
Sources cited by Health Canada (6)
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
- Panax ginseng
Read the warning, when it applies and the studies cited
PANAX GINSENG
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Chin RKH. Ginseng and common pregnancy disorders. Asia-Oceania Journal of Obstetrics and Gynaecology 1991;17(4):379-380. PubMed
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. The Canadian Journal of Clinical Pharmacology 2008;15(1):e87-e94.
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18(10):1373-1375. PubMed Clinical trial
- Tetsutani T, Yamamura M, Yamaguchi T, Onoyama O, Kono M. Can red ginseng control blood glucose in diabetic patients. The Ginseng Review 2000;28:44-47.
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dasgupta A, Reyes MA. Effect of Brazillian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab Fragment of antidigoxin antibody (Digiband). American Journal of Clinical Pathology 2005;124(2):229-236. PubMed
- Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible case. Journal of Clinical Psychopharmacology 1995;15(6):447-448. PubMed Case report
- Janetzki K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy 1997;54(6):692-693.
- Jones BD, Runikis AM. Interaction of ginseng with phenelzine. Journal of Clinical Pharmacology 1987;7(3):201-202. PubMed Case report
- Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine 2008a;14(6):715-721. PubMed Randomised trial
- Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. Journal of Clinical Psychopharmacology 1988;8(4):235. PubMed Case report
- Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. Journal of Clinical Psychopharmacology 1985;5(2):65. PubMed Case report
Contraindications
Condition of application: Traditional Chinese Medicine.
Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).
Sources cited by Health Canada (1)
- Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
Known adverse reactions
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).
Sources cited by Health Canada (8)
- Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-344. PubMed Systematic review
- de Andrade E, de Masquita AA, de Almeida Claro J, de Andrade PM, Ortiz V, Paranhos M, Srougi M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology 2007;9(2):241-244.
- Ellis JM, Reddy P. Effects of Panax ginseng on quality of life. The Annals of Pharmacotherapy 2002;36(3):375-379. PubMed Randomised trial
- Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008b;22(3):222-226. PubMed Randomised trial
- Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis. Clinical Drug Investigation 2001;21(1):41-45.
- Siegel RK. Ginseng abuse syndrome. Problems with the panacea. The Journal of the American Medical Association 1979;241(15):1614-1615. PubMed
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Irvingia gabonensis
Read the warning, when it applies and the studies cited
AFRICAN WILD MANGO - IRVINGIA GABONENSIS
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Ross 2011; Ngondi et al. 2009; Adamson et al. 1986).
Sources cited by Health Canada (3)
- Adamson I, Okafor C, Abu-Bakare A. Erythrocyte membrane ATPases in diabetes: effect of dikanut (Irvingia gabonensis). Enzyme 1986; 36(3): 212-215. PubMed
- Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids in Health and Disease 2009; 8:7. PubMed Randomised trial
- Ross MS. A proprietary seed extract of Irvingia gabonensis is found to be effective in reducing body weight and improving metabolic parameters in overweight humans. Holistic Nursery Practice 2011; 235(4): 215-217.
Condition of application: Antioxidant, cholesterol, glucose.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant.
Contraindications
Condition of application: Weight management.
Do not use if you are pregnant.
Known adverse reactions
Stop use if you experience symptoms of hypoglycaemia including feelings of anxiety, dizziness, tremor, sweating, nausea or headache (Adamson et al. 1986; Ngondi et al. 2009; Oben et al. 2008a,b).
Sources cited by Health Canada (3)
- Adamson I, Okafor C, Abu-Bakare A. Erythrocyte membrane ATPases in diabetes: effect of dikanut (Irvingia gabonensis). Enzyme 1986; 36(3): 212-215. PubMed
- Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids in Health and Disease 2009; 8:7. PubMed Randomised trial
- Oben JE, Ngondi JL, Blum K. Inhibition of Irvingina gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up- regulation of the adiponectin gene. Lipids in Health and Disease 2008a; 7:44. PubMed
- Silybum marianum
Read the warning, when it applies and the studies cited
MILK THISTLE - SILYBUM MARIANUM
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).
Sources cited by Health Canada (2)
- Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
- Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Nature in Capsule Albumin Classic S (Infinitree Corp.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80123067-nature-in-capsule-albumin-classic-s, updated 7 February 2023.